KAPOSI SARCOMA
Clinical trials for KAPOSI SARCOMA explained in plain language.
Never miss a new study
Get alerted when new KAPOSI SARCOMA trials appear
Sign up with your email to follow new studies for KAPOSI SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets rare, aggressive cancer
Disease control Recruiting nowThis phase 2 trial is testing whether combining two chemotherapy drugs—Abraxane and liposomal doxorubicin—can shrink tumors in people with advanced or unresectable angiosarcoma, a rare and aggressive cancer of blood vessels. The study will enroll 69 patients who have already trie…
Matched conditions: KAPOSI SARCOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail targets Virus-Linked cancers in early trial
Disease control Recruiting nowThis phase 1 study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors. Up to 58 people with Kapo…
Matched conditions: KAPOSI SARCOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo aims to outsmart kaposi sarcoma tumors
Disease control Recruiting nowThis study tests two drugs, PDS01ADC and M7824, that work with the immune system to fight Kaposi sarcoma (KS), a cancer often linked to HIV or organ transplants. The trial enrolls 80 adults with advanced KS that has not responded well to prior therapy. Participants receive PDS01A…
Matched conditions: KAPOSI SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Could a Lab-Made protein help fight HIV-Related cancer?
Disease control Recruiting nowThis study tests a lab-made human protein called CYT107 in 55 people with HIV and Kaposi sarcoma. The protein aims to boost T cells, which may help shrink cancer tumors. Participants receive weekly injections for up to 4 weeks, with follow-up for 3 years.
Matched conditions: KAPOSI SARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Could a breast cancer drug tame kaposi sarcoma?
Disease control Recruiting nowThis study tests a drug called abemaciclib, already used for breast cancer, in people with Kaposi sarcoma (KS), both with and without HIV. The goal is to find a safe dose and see if it can shrink KS tumors. About 111 adults will take the drug daily in 28-day cycles until their ca…
Matched conditions: KAPOSI SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for rare cancers: immunotherapy drug targets tumors regardless of origin
Disease control Recruiting nowThis study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…
Matched conditions: KAPOSI SARCOMA
Phase: PHASE2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Could a $4 heart pill beat a cancer? new trial tests propranolol for kaposi sarcoma
Disease control Recruiting nowThis phase II trial tests whether propranolol, a cheap and widely available blood pressure medicine, can shrink Kaposi sarcoma tumors in adults. The study enrolls 25 people with measurable lesions, including those with HIV. Researchers hope for a 45% response rate with fewer side…
Matched conditions: KAPOSI SARCOMA
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could a cancer pill shrink kaposi tumors?
Disease control Recruiting nowThis study tests a drug called ixazomib in people with Kaposi sarcoma, a type of skin cancer. The drug works by blocking enzymes that cancer cells need to grow. Researchers want to see if it can shrink tumors and will monitor side effects. About 41 adults with measurable skin les…
Matched conditions: KAPOSI SARCOMA
Phase: PHASE2 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New virus therapy takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…
Matched conditions: KAPOSI SARCOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New 3D scanner could revolutionize how doctors measure kaposi sarcoma
Knowledge-focused Recruiting nowThis study will test a new 3D imaging device called SkinScan3D to see if it can measure Kaposi Sarcoma skin lesions more accurately and consistently than the current manual method. Researchers will compare the two methods in 300 adults with confirmed Kaposi Sarcoma who are starti…
Matched conditions: KAPOSI SARCOMA
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Scientists seek tissue samples to unlock HIV-Cancer mysteries
Knowledge-focused Recruiting nowThis study collects blood and tissue samples from 200 adults with HIV and certain cancers (like Kaposi sarcoma, lymphoma, or anal cancer) to help researchers understand how HIV and cancer are connected. Participants donate samples, which are stored for future research. There is n…
Matched conditions: KAPOSI SARCOMA
Sponsor: AIDS Malignancy Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Scientists launch Decade-Long watch on kaposi sarcoma
Knowledge-focused Recruiting nowThis study follows 150 adults with Kaposi sarcoma (KS) for up to 10 years to learn how the disease behaves, why it comes back, and how it affects the immune system and organs. Participants will have regular check-ups, scans, and biopsies, but no new treatments are being tested. T…
Matched conditions: KAPOSI SARCOMA
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists probe blood vessel role in skin disorders
Knowledge-focused Recruiting nowThis study looks at how abnormal blood vessel growth (angiogenesis) contributes to various skin diseases like rosacea, psoriasis, and certain tumors. Researchers will collect skin samples from 85 volunteers aged 16 and older to analyze markers of angiogenesis. The goal is to bett…
Matched conditions: KAPOSI SARCOMA
Sponsor: University of California, Irvine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
New 3D camera could revolutionize how we track kaposi sarcoma
Knowledge-focused Recruiting nowThis study tests a new 3D imaging device called SkinScan3D to see if it can take better pictures of Kaposi sarcoma (KS) skin lesions than standard 2D photos. KS lesions can change in height when they respond to treatment, which 2D photos miss. The study will enroll 30 adults with…
Matched conditions: KAPOSI SARCOMA
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Peer support boosts cancer care for HIV-positive youth in zambia
Knowledge-focused Recruiting nowThis study looks at whether peer education and support can help more adolescents and young adults (ages 15-39) living with HIV get screened for cancer and stick with their cancer treatment. Researchers will work with 4,100 participants in Zambia to improve early diagnosis and tre…
Matched conditions: KAPOSI SARCOMA
Phase: NA • Sponsor: Implenomics • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC